Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 5/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946856 | 0.68 | SIRT3 (0.36) | SIRT3TDP1LMNAALDH1A1ADORA3 | |
| SCHEMBL23302086 | 0.67 | — | — | |
| SCHEMBL20555873 | 0.67 | PARP1 (0.39) | SIRT3TDP1LMNAALDH1A1NNMT | |
| SCHEMBL29827533 | 0.67 | PARP1 (0.39) | SIRT3TDP1LMNAALDH1A1NNMT | |
| SCHEMBL6302474 | 0.67 | NNMT (0.42) | ALDH1A1NNMTKDM4ESMN1; SMN2 | |
| SCHEMBL9087886 | 0.66 | — | — | |
| SCHEMBL3460085 | 0.65 | SIRT3 (0.37) | SIRT3TDP1LMNAALDH1A1NNMT | |
| SCHEMBL4926679 | 0.65 | SIRT3 (0.37) | SIRT3TDP1NNMTADORA3SIRT6 | |
| SCHEMBL20765628 | 0.65 | NNMT (0.47) | SIRT3TDP1NNMTKDM4EGABRP | |
| SCHEMBL3090048 | 0.65 | NOS3 (0.48) | SIRT3TDP1NNMTGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013004617-A1 | PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | WO | claimed |
| US-20130005743-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-03 | — | — | US | claimed |
| WO-2013004617-A1 | PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. LUNDBECK A/S (DK) | 2013-01-10 | — | — | WO | disclosed |
| US-20130005743-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2013-01-03 | — | — | US | disclosed |
| US-6642254-B2 | Administering compounds, e.g., 8-methoxy-2-trifluoromethylquinoline-5-carboxylic acid (3,5-dichloro-1-oxypyridin-4-yl)amide for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase | DARWIN DISCOVERY, LTD. (GB) | 2003-11-04 | — | — | US | disclosed |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-12-05 | — | — | US | disclosed |
| US-6410559-B2 | 3,5-DISUBSTITUTED-(OXYPYRIDINE-4-YL)AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITOR TO TREAT INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE | DARWIN DISCOVERY, LTD. (GB) | 2002-06-25 | — | — | US | disclosed |
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2001-09-27 | — | — | US | disclosed |
| US-6262070-B1 | E.G., 8-METHOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYLIC ACID(3,5-DICHLORO-1-OXYPYRIDIN-4-YL)AMIDE; TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE | DARWIN DISCOVERY LTD. (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1045845-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | Darwin Discovery Limited (GB) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000026208-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005743-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | SIRT3 236/4885TDP1 2407/4885LMNA 3278/4885 |
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | SIRT3 45/4885TDP1 3977/4885LMNA 2456/4885 |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | SIRT3 45/4885TDP1 3977/4885LMNA 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.